SARS-CoV2 and immunosuppression: A double-edged sword

被引:34
|
作者
Lai, Quirino [1 ]
Spoletini, Gabriele [2 ]
Bianco, Giuseppe [2 ]
Graceffa, Dario [3 ]
Agnes, Salvatore [2 ]
Rossi, Massimo [2 ]
Lerut, Jan [4 ]
机构
[1] Sapienza Univ Rome, Hepatobiliary & Organ Transplantat Unit, Umberto Polyclin Rome 1, Viale Policlin 155, Rome, Italy
[2] Fdn Policlin Univ A Gemelli IRCCS, Gen Surg & Liver Transplantat, Rome, Italy
[3] IRCCS, San Gallicano Dermatol Inst, Dept Clin Dermatol, Ctr Study & Treatment Psoriasis, Rome, Italy
[4] Univ Catholique Louvain UCL, Inst Expt & Clin Res IREC, Brussels, Belgium
关键词
Coronavirus; COVID-19; cyclosporine; SARS; steroids; tacrolimus; RESPIRATORY-SYNDROME SARS; MERS-COV INFECTION; CORTICOSTEROID TREATMENT; COVID-19; REPLICATION; THERAPY;
D O I
10.1111/tid.13404
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Severe acute respiratory syndrome Coronavirus 2 (SARS-Cov2) outbreak has caused a pandemic rapidly impacting on the way of life of the entire world. This impact in the specific setting of transplantation and immunosuppression has been poorly explored to date. Discordant data exist on the impact of previous coronavirus outbreaks on immunosuppressed patients. Overall, only a very limited number of cases have been reported in literature, suggesting that transplanted patients not necessarily present an increased risk of severe SARS-Cov2-related disease compared to the general population. We conducted a literature review related to the impact of immunosuppression on coronavirus infections including case reports and series describing immunosuppression management in transplant recipients. The role of steroids, calcineurin inhibitors, and mycophenolic acid has been explored more in detail. A point-in-time snapshot of the yet released literature and some considerations in relation to the use of immunosuppression in SARS-Cov2 infected transplant recipients are provided here for the physicians dealing with immunocompromised patients.
引用
收藏
页数:10
相关论文
共 50 条
  • [1] SARS-CoV-2 variants: A double-edged sword?
    Jogalekar, Manasi P.
    Veerabathini, Anurag
    Gangadaran, Prakash
    EXPERIMENTAL BIOLOGY AND MEDICINE, 2021, 246 (15) : 1721 - 1726
  • [2] Natalizumab: A Double-Edged Sword?
    DeAngelis, Lisa M.
    ANNALS OF NEUROLOGY, 2009, 66 (03) : 262 - 263
  • [3] Angiotensin-converting enzyme 2 in severe acute respiratory syndrome coronavirus and SARS-CoV-2: A double-edged sword?
    Yan, Tiantian
    Xiao, Rong
    Lin, Guoan
    FASEB JOURNAL, 2020, 34 (05) : 6017 - 6026
  • [4] Lipid rafts as viral entry routes and immune platforms: A double-edged sword in SARS-CoV-2 infection?
    Roncato, Rossana
    Angelini, Jacopo
    Pani, Arianna
    Talotta, Rossella
    BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS, 2022, 1867 (06):
  • [5] A double edged-sword - The Complement System during SARS-CoV-2 infection
    Santiesteban-Lores, Lazara Elena
    Amamura, Thais Akemi
    da Silva, Tiago Francisco
    Midon, Leonardo Moura
    Carneiro, Milena Carvalho
    Isaac, Lourdes
    Bavia, Lorena
    LIFE SCIENCES, 2021, 272
  • [6] Notch and cancer: a double-edged sword
    Koch, U.
    Radtke, F.
    CELLULAR AND MOLECULAR LIFE SCIENCES, 2007, 64 (21) : 2746 - 2762
  • [7] Calcineurin inhibitors: a double-edged sword
    Ume, Adaku C.
    Wenegieme, Tara-Yesomi
    Williams, Clintoria R.
    AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY, 2021, 320 (03) : F336 - F341
  • [8] Iodine and Hyperthyroidism: A Double-Edged Sword
    Braverman, Kate D.
    Pearce, Elizabeth N.
    ENDOCRINE PRACTICE, 2025, 31 (03) : 390 - 395
  • [9] Angiotensin Converting Enzyme 2 A Double-Edged Sword
    Wang, Kaiming
    Gheblawi, Mahmoud
    Oudit, Gavin Y.
    CIRCULATION, 2020, 142 (05) : 426 - 428
  • [10] Thrombocytopenia and thrombosis: a double-edged sword
    Nyo, Myat Tun Lin
    Kalla, Asgar Ali
    CLINICAL RHEUMATOLOGY, 2014, 33 (04) : 587 - 590